Kaiser Permanente denied your IVIG and immunoglobulin? Here is what to do next

Why Kaiser Permanente denies IVIG and immunoglobulin

Kaiser Permanente is a vertically integrated system, the insurer (Kaiser Foundation Health Plan), medical groups, and hospitals operate as one closed network. Because the treating physician and the plan share an employer, the appeal pathway looks different from a typical PPO denial: the dispute is often with the in-house utilization-review decision rather than with a separate carrier.

For IVIG and immunoglobulin specifically: Intravenous and subcutaneous immunoglobulin (IVIG, SCIG) is expensive, infused repeatedly, and reviewed against a short list of accepted diagnoses. Denials say 'not medically necessary' or 'experimental' for the specific condition, or move the drug to a different benefit or site of care.

What Kaiser Permanente denies for IVIG and immunoglobulin

The IVIG and immunoglobulin services most often denied:

• IVIG for CIDP, myasthenia gravis, dermatomyositis, or autoimmune encephalitis
• Continuation after the initial authorization period when response is not documented
• Dose or frequency above the policy's stated range
• Site-of-care changes: hospital outpatient infusion moved to home or a standalone center
• Subcutaneous immunoglobulin when the plan prefers intravenous

Why IVIG and immunoglobulin claims get denied

A typical Kaiser Permanente IVIG and immunoglobulin denial almost always cites one of these reasons. Each one maps to a specific rebuttal in the appeal:

• Diagnosis not on the plan's list of covered indications
• Required baseline labs (immunoglobulin levels, vaccine response, nerve conduction studies) not in the record
• No documented failure of first-line therapy where the policy requires it
• Response to prior IVIG cycles not documented in measurable terms
• Plan classifies the use as experimental or investigational

The Kaiser Permanente appeal process

Appeal levels: Internal grievance / appeal, then state external review (e.g. DMHC IMR in California). Medicare Advantage follows the federal 5-level ladder: plan → IRE (MAXIMUS) → ALJ → Council → federal court.

Carrier timing: 180 days from denial for internal appeal in most commercial plans; 60 days between each level for Medicare Advantage. Expedited urgent decisions within 72 hours.

IVIG timing: Ongoing infusions make most IVIG appeals urgent: request expedited review and expect a decision within 72 hours (29 CFR 2560.503-1(f)(2)(i); 42 CFR 422.584 for Medicare Advantage). Internal appeal filing window: at least 180 days for commercial and employer plans; 65 days for Medicare Advantage; 60 days for Part D redetermination (42 CFR 423.582). External review must be requested within 4 months of the final internal denial for ACA-covered plans.

What we know about Kaiser Permanente: We coordinate Kaiser appeals through the member-services grievance system while preserving the IMR / external-review pathway. Documenting the closed-network constraint is often the unlock on out-of-plan-referral cases.

Common Kaiser Permanente denial patterns for IVIG and immunoglobulin

• Internal grievance before external review. Kaiser members file a grievance with Member Services first. In California, Kaiser's largest market, DMHC oversight applies, and the IMR (Independent Medical Review) pathway opens after Kaiser's final internal decision. Members in other states route to their state DOI or to an IRO.
• Out-of-network referral denials. Because Kaiser is closed-network, most non-emergent out-of-plan care must be authorized in advance. Denials are common when a member seeks a specialist outside the system; the strongest appeal lane is a clinical-necessity argument that the in-network alternative is unavailable or inadequate.
• Medicare Advantage escalates to MAXIMUS. Kaiser's Senior Advantage plans follow the federal 5-level Medicare Advantage ladder. After Kaiser's plan-level reconsideration, the case goes to MAXIMUS Federal Services (the IRE), an external escalation that frequently reverses plan denials when the clinical record is complete.

How to win your Kaiser Permanente IVIG and immunoglobulin appeal

Strategy for IVIG and immunoglobulin: Request the plan's immunoglobulin policy and the reviewer's specialty. Have the treating specialist write to each criterion: diagnosis with supporting labs or electrodiagnostic studies, prior therapies and results, measurable response to IVIG, and dosing rationale. For off-label uses, attach the guideline or peer-reviewed evidence the specialist relies on and identify it accurately. If the denial is 'experimental', the external review process specifically covers that determination (45 CFR 147.136(d)).

Filed against Kaiser Permanente, that strategy rides on this procedural spine:

1. Procedural-rights anchor. Every Kaiser Permanente denial triggers ERISA § 503 or 45 C.F.R. § 147.136 procedural rights. The cover letter invokes these in the opening paragraph to lock the timeline and force criteria disclosure.
2. Criteria-disclosure demand. Kaiser Permanente frequently denies on "not medically necessary" without disclosing the clinical criteria applied. Once disclosed, those criteria become the rebuttal map.
3. Controlling-standard citation. Plans compare the diagnosis to their immunoglobulin policy, which typically lists FDA-labeled indications (primary immunodeficiency, immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, Kawasaki disease, and others) and selected off-label uses supported by published evidence. Medicare Part B covers immunoglobulin for primary immunodeficiency at home under 42 CFR 410.10 and the home IVIG benefit; other indications follow local coverage determinations in the Medicare Coverage Database. Plan criteria must be disclosed on request (29 CFR 2560.503-1(m)(8); 45 CFR 147.136).
4. Treating-provider attestation. A letter from the treating physician addressing each criterion in Kaiser Permanente's own policy language. This is the single strongest evidentiary element.
5. Requested action. A specific demand to reverse the IVIG and immunoglobulin denial and approve the service, not a general "please reconsider."

Documents you'll need for your Kaiser Permanente IVIG and immunoglobulin appeal

• The denial letter naming the criterion or policy applied
• Specialist's notes with diagnosis, labs, and electrodiagnostic or imaging results
• Record of prior therapies and outcomes
• Infusion records showing dose, frequency, and documented response
• The plan's immunoglobulin policy (request it in writing)

What a IVIG and immunoglobulin appeal can recover

Typical recovery for IVIG and immunoglobulin cases runs Immunoglobulin is among the most expensive recurring therapies; a denied course commonly represents thousands of dollars per infusion in billed charges.. The exact figure depends on the specific service and your plan's contracted rates.

Kaiser Permanente IVIG and immunoglobulin appeals: frequently asked questions

What Apellica does for Kaiser Permanente IVIG and immunoglobulin appeals

We file appeals against Kaiser Permanente specifically configured to its internal review process. Every IVIG and immunoglobulin appeal embeds the criteria-disclosure demand, the procedural-rights anchor, the controlling-standard citation above, treating-provider attestation language, and the peer-reviewed evidence relevant to the denied service.

Cost: $0 upfront. We work on contingency for Kaiser Permanente appeals, if the appeal succeeds, we collect a percentage of the recovered claim value. If it fails, you owe nothing.

Related Kaiser Permanente guides

• Kaiser Permanente surgery denials appeal guide
• Kaiser Permanente mri and imaging denials appeal guide
• Kaiser Permanente medication and prescription denials appeal guide
• Kaiser Permanente medicare denials appeal guide

IVIG and immunoglobulin guides for other carriers

• UnitedHealthcare IVIG and immunoglobulin appeal guide
• Aetna (CVS Health) IVIG and immunoglobulin appeal guide
• Cigna (Evernorth) IVIG and immunoglobulin appeal guide
• Anthem / BlueCross BlueShield IVIG and immunoglobulin appeal guide